Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2930)	1/25/2011 2:39:34 PM
From: tuck	Respond to of 3158

Size of P2 and caveats re cancer vaccines notwithstanding, I have to admit their data looks pretty good: biovex.com The P3 is open label, wonder why. OTOH, the requirement for a durable response of over six months is a pretty high bar, open label or not, isn't it? If they succeed without a problematic safety signal, I'd think the FDA would go for it. Well, I certainly hope it works out. Initial market reaction is neutral. I see their chief commercial officer is Steve Kelly. Lately of InnoVive. Started his career at AMGN, back in the 90s. Cheers, Tuck